{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T21:07:16Z","timestamp":1774472836744,"version":"3.50.1"},"reference-count":215,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Pharmacology"],"abstract":"<jats:p>The progress of contemporary pharmacology is deeply linked to pharmacokinetics (PK) and its quantitative exploration through PK modeling. By offering a robust mathematical framework to describe and predict drug absorption, distribution, metabolism, and excretion (ADME), PK modeling is essential for designing and optimizing safe and effective dosing regimens and for advancing personalized medicine and model-informed drug development (MIDD). The reliability of population PK (popPK) and physiologically based PK (PBPK) models depends on high-quality experimental data to estimate PK parameters. Traditional PK data sources include clinical studies, preclinical animal models, and human-derived cell lines. Although considered gold standards, these sources have significant drawbacks. Clinical trials are often restricted by ethical, logistical, and financial challenges and often include homogenous populations that fail to reflect real-world interindividual variability. Similarly, animal and cell-based models lack the physiological complexity of humans, leading to discrepancies between preclinical predictions and clinical outcomes. These constraints have stimulated interest in alternative platforms that more faithfully recapitulate human physiology and interindividual diversity. This review explores the potential of organoids as a novel or complementary source of PK-relevant data. Organoids, three-dimensional (3D) stem cell-derived structures, mimic the cellular architecture, functional heterogeneity, and physiological responses of human tissues. In particular, intestinal, liver, and kidney organoids preserve essential cellular features of ADME processes, positioning them as promising tools for integration into popPK and PBPK modeling frameworks.<\/jats:p>","DOI":"10.3390\/futurepharmacol5040074","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:52:59Z","timestamp":1765813979000},"page":"74","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Organoids as a Revolutionary Data Source for Pharmacokinetic Modeling: A Comprehensive Review"],"prefix":"10.3390","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-4957","authenticated-orcid":false,"given":"Lara","family":"Marques","sequence":"first","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"ref_1","unstructured":"International Council for Harmonisation (1994). ICH E7 Studies in Support of Special Populations: Geriatrics\u2014Scientific Guideline, International Council for Harmonisation."},{"key":"ref_2","unstructured":"Food and Drug Administration (1999). Guidance for Industry Population Pharmacokinetics."},{"key":"ref_3","unstructured":"European Medicines Agency (2004). Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Decreased Renal Function\u2014Scientific Guideline."},{"key":"ref_4","unstructured":"Food and Drugs Administration (2004). Challenge and Opportunity on the Critical Path to New Medical Products."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bcp.15728","article-title":"The Trajectory of Pharmacometrics to Support Drug Licensing and Labelling","volume":"91","author":"Dunn","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"907461","DOI":"10.1155\/2011\/907461","article-title":"Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development","volume":"2011","author":"Khalil","year":"2011","journal-title":"Biomed. Res. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.drudis.2022.04.015","article-title":"Opportunities and Challenges of Physiologically Based Pharmacokinetic Modeling in Drug Delivery","volume":"27","author":"Wang","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/psp.2013.41","article-title":"Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.1013","article-title":"Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective","volume":"104","author":"Shebley","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40495-016-0059-9","article-title":"Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: A Transition from Academic Curiosity to Regulatory Acceptance","volume":"2","author":"Jamei","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/psp.2013.14","article-title":"Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development\u2014Part 2: Introduction to Pharmacokinetic Modeling Methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/psp.2012.4","article-title":"Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_13","unstructured":"Krivelevich, I., and Lin, S. (2021, January 24\u201327). Visualization of Sparse PK Concentration Sampling Data, Step by Step (Improvement by Improvement). Proceedings of the PharmaSUG 2021, Virtual."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/17407745211038524","article-title":"Characteristics of Available Studies and Dissemination of Research Using Major Clinical Data Sharing Platforms","volume":"18","author":"Vazquez","year":"2021","journal-title":"Clin. Trials"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/cts.13004","article-title":"A Pharmacokinetic Simulation Study to Assess the Performance of a Sparse Blood Sampling Approach to Quantify Early Drug Exposure","volume":"14","author":"Sathe","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF02353491","article-title":"Comparison of Some Practical Sampling Strategies for Population Pharmacokinetic Studies","volume":"24","author":"Jonsson","year":"1996","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Weber, W., Martinez, J.-M., R\u00fcppel, D., and Lockwood, G. (2011). Population Pharmacokinetics in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology, Springer.","DOI":"10.1007\/978-3-540-89891-7_18"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Friedman, L.M., Furberg, C.D., DeMets, D.L., Reboussin, D.M., and Granger, C.B. (2015). Fundamentals of Clinical Trials, Springer International Publishing.","DOI":"10.1007\/978-3-319-18539-2"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5455\/aim.2008.16.219-225","article-title":"Evidence Based Medicine\u2014New Approaches and Challenges","volume":"16","author":"Masic","year":"2008","journal-title":"Acta Inform. Medica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence Based Medicine: What It Is and What It Isn\u2019t","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The Levels of Evidence and Their Role in Evidence-Based Medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","article-title":"Comparing Clinical Trial Population Representativeness to Real-World Populations: An External Validity Analysis Encompassing 43\u2008895 Trials and 5\u2008685\u2008738 Individuals across 989 Unique Drugs and 286 Conditions in England","volume":"3","author":"Tan","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e012265","DOI":"10.1136\/bmjopen-2016-012265","article-title":"Exclusion of Patients with Concomitant Chronic Conditions in Ongoing Randomised Controlled Trials Targeting 10 Common Chronic Conditions and Registered at ClinicalTrials.gov: A Systematic Review of Registration Details","volume":"6","author":"Dechartres","year":"2016","journal-title":"BMJ Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1037\/hea0000726","article-title":"Multimorbidity in Randomized Controlled Trials of Behavioral Interventions: A Systematic Review","volume":"38","author":"Stoll","year":"2019","journal-title":"Health Psychol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1200\/JCO.2005.00.141","article-title":"Systematic Review of Barriers to the Recruitment of Older Patients with Cancer Onto Clinical Trials","volume":"23","author":"Townsley","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s11606-010-1629-x","article-title":"Examining the Evidence: A Systematic Review of the Inclusion and Analysis of Older Adults in Randomized Controlled Trials","volume":"26","author":"Zulman","year":"2011","journal-title":"J. Gen. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"pky059","DOI":"10.1093\/jncics\/pky059","article-title":"Extent of Exclusions for Chronic Conditions in Breast Cancer Trials","volume":"2","author":"Kronish","year":"2018","journal-title":"JNCI Cancer Spectr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical Journals","volume":"297","author":"Toren","year":"2007","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13063-020-4139-0","article-title":"Exclusion Rates in Randomized Controlled Trials of Treatments for Physical Conditions: A Systematic Review","volume":"21","author":"He","year":"2020","journal-title":"Trials"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2015080","DOI":"10.1001\/jamanetworkopen.2020.15080","article-title":"Assessment of the Generalizability of Clinical Trials of Delirium Interventions","volume":"3","author":"Martin","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e006413","DOI":"10.1136\/bmjopen-2014-006413","article-title":"Risk of Developing Multimorbidity across All Ages in an Historical Cohort Study: Differences by Sex and Ethnicity","volume":"5","author":"Boyd","year":"2015","journal-title":"BMJ Open"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kon\u00e9 Pefoyo, A.J., Bronskill, S.E., Gruneir, A., Calzavara, A., Thavorn, K., Petrosyan, Y., Maxwell, C.J., Bai, Y., and Wodchis, W.P. (2015). The Increasing Burden and Complexity of Multimorbidity. BMC Public Health, 15.","DOI":"10.1186\/s12889-015-1733-2"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.3399\/bjgp18X695465","article-title":"The Epidemiology of Multimorbidity in Primary Care: A Retrospective Cohort Study","volume":"68","author":"Cassell","year":"2018","journal-title":"Br. J. Gen. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1016\/S2468-2667(19)30222-1","article-title":"Multimorbidity\u2014A Defining Challenge for Health Systems","volume":"4","author":"Ezzati","year":"2019","journal-title":"Lancet Public Health"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3399\/bjgp11X556146","article-title":"Polypharmacy: One of the Greatest Prescribing Challenges in General Practice","volume":"61","author":"Payne","year":"2011","journal-title":"Br. J. Gen. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41256-023-00311-4","article-title":"Prevalence and Trends of Polypharmacy in U.S. Adults, 1999\u20132018","volume":"8","author":"Wang","year":"2023","journal-title":"Glob. Health Res. Policy"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Delara, M., Murray, L., Jafari, B., Bahji, A., Goodarzi, Z., Kirkham, J., Chowdhury, Z., and Seitz, D.P. (2022). Prevalence and Factors Associated with Polypharmacy: A Systematic Review and Meta-Analysis. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03388-7"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jamda.2019.10.022","article-title":"Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews","volume":"21","author":"Davies","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4103\/0972-2327.143984","article-title":"Influence of Trial Design, Heterogeneity and Regulatory Environment on the Results of Clinical Trials: An Appraisal in the Context of Recent Trials on Acute Stroke Intervention","volume":"17","author":"Srijithesh","year":"2014","journal-title":"Ann. Indian. Acad. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing Diversity in Clinical Trials: Overcoming Critical Barriers","volume":"44","author":"Clark","year":"2019","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1056\/NEJMp2215609","article-title":"Why Diverse Clinical Trial Participation Matters","volume":"388","author":"Schwartz","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpt.61","article-title":"Racial\/Ethnic Differences in Drug Disposition and Response: Review of Recently Approved Drugs","volume":"97","author":"Ramamoorthy","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/jwh.2012.3733","article-title":"Dialogues on Diversifying Clinical Trials: Successful Strategies for Engaging Women and Minorities in Clinical Trials","volume":"21","author":"Coakley","year":"2012","journal-title":"J. Women\u2019s Health"},{"key":"ref_44","unstructured":"U.S. Census Bureau (2025, August 07). Racial and Ethnic Diversity in the United States: 2010 Census and 2020 Census, Available online: https:\/\/www.census.gov\/library\/visualizations\/interactive\/racial-and-ethnic-diversity-in-the-united-states-2010-and-2020-census.html."},{"key":"ref_45","unstructured":"Food and Drug Administration (2016). Collection of Race and Ethnicity Data in Clinical Trials. Guidance for Industry and Food and Drug Administration Staff."},{"key":"ref_46","unstructured":"Food and Drug Administration (2020). Enhancing the Diversity of Clinical Trial Populations\u2014Eligibility Criteria, Enrollment Practices, and Trial Designs. Guidance for Industry."},{"key":"ref_47","unstructured":"Food and Drug Administration (2022). Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials. Guidance for Industry."},{"key":"ref_48","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiologic Health (CDRH), and Oncology Center of Excellence (OCE) (2024). Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products. Guidance for Industry."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/ecp.11.43","article-title":"Innovative Clinical Trial Design for Pediatric Therapeutics","volume":"4","author":"Laughon","year":"2011","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1542\/peds.2007-1529","article-title":"Improving Pediatric Dosing through Pediatric Initiatives: What We Have Learned","volume":"121","author":"Rodriguez","year":"2008","journal-title":"Pediatrics"},{"key":"ref_51","unstructured":"Food and Drug Administration, and Center for Drug Evaluation and Research (2022). General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products Guidance for Industry Clinical Pharmacology Revision 1 Contains Nonbinding Recommendations."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0006-2952(92)90010-G","article-title":"Effect of Age and Gender on the Activity of Human Hepatic CYP3A","volume":"44","author":"Hunt","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2125.2004.02096.x","article-title":"Drug Metabolism and Ageing","volume":"57","author":"Kinirons","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/bmj.3.5775.607","article-title":"Effect of Age and Sex on Human Drug Metabolism","volume":"3","author":"Crooks","year":"1971","journal-title":"Br. Med. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0009-9236(97)90166-1","article-title":"Age and Cytochrome P450-Linked Drug Metabolism in Humans: An Analysis of 226 Subjects with Equal Histopathologic Conditions","volume":"61","author":"Sotaniemi","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40272-020-00400-8","article-title":"External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study","volume":"22","author":"Hartman","year":"2020","journal-title":"Pediatr. Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/bcp.16335","article-title":"Recommended Approaches for Integration of Population Pharmacokinetic Modelling with Precision Dosing in Clinical Practice","volume":"91","author":"Berezowska","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.12788\/jhm.3380","article-title":"Methodologic Progress Note: Opportunistic Sampling for Pharmacology Studies in Hospitalized Children","volume":"16","author":"Girdwood","year":"2020","journal-title":"J. Hosp. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1002\/jcph.1053","article-title":"Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children","volume":"58","author":"Balevic","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/AAC.00569-08","article-title":"Population Pharmacokinetics of Fluconazole in Young Infants","volume":"52","author":"Wade","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1067\/mcp.2000.105353","article-title":"Vancomycin Population Pharmacokinetics in Neonates","volume":"67","author":"Dehoog","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/jac\/dkl244","article-title":"Population Pharmacokinetics of Gentamicin in Premature Newborns","volume":"58","author":"Garcia","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jcph.1773","article-title":"Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of \u0392-Lactam Antibiotics in Critically Ill Children","volume":"61","author":"Tang","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e01533-23","DOI":"10.1128\/aac.01533-23","article-title":"Opportunistic Dried Blood Spot Sampling Validates and Optimizes a Pediatric Population Pharmacokinetic Model of Metronidazole","volume":"68","author":"Randell","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/psp4.13056","article-title":"Tutorial on Model Selection and Validation of Model Input into Precision Dosing Software for Model-informed Precision Dosing","volume":"12","author":"Taylor","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/psp4.12611","article-title":"Approaches to Handling Missing or \u201cProblematic\u201d Pharmacology Data: Pharmacokinetics","volume":"10","author":"Irby","year":"2021","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1475-2875-11-143","article-title":"Optimal Designs for Population Pharmacokinetic Studies of the Partner Drugs Co-Administered with Artemisinin Derivatives in Patients with Uncomplicated Falciparum Malaria","volume":"11","author":"Jamsen","year":"2012","journal-title":"Malar. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0169-2607(03)00073-7","article-title":"POPED, a Software for Optimal Experiment Design in Population Kinetics","volume":"74","author":"Foracchia","year":"2004","journal-title":"Comput. Methods Programs Biomed."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Carroll, R.J., Ruppert, D., Stefanski, L.A., and Crainiceanu, C.M. (2006). Measurement Error in Nonlinear Models, CRC Press.","DOI":"10.1201\/9781420010138"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Santalo, O., Baig, U., Poulakos, M., and Brown, D. (2016). Early Vancomycin Concentrations and the Applications of a Pharmacokinetic Extrapolation Method to Recognize Sub-Therapeutic Outcomes. Pharmacy, 4.","DOI":"10.3390\/pharmacy4040037"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00228-013-1576-7","article-title":"Practical Recommendations for Population PK Studies with Sampling Time Errors","volume":"69","author":"Choi","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10928-005-0014-6","article-title":"Optimal Blood Sampling Time Windows for Parameter Estimation Using a Population Approach: Design of a Phase II Clinical Trial","volume":"32","author":"Chenel","year":"2005","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/bimj.201300283","article-title":"Sharing Clinical Trial Data on Patient Level: Opportunities and Challenges","volume":"57","author":"Koenig","year":"2015","journal-title":"Biom. J."},{"key":"ref_74","unstructured":"(2025, August 13). Clinical Study Data Request. Available online: https:\/\/www.clinicalstudydatarequest.com\/Default.aspx."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e032334","DOI":"10.1136\/bmjopen-2019-032334","article-title":"Clinical Trial Data Sharing: Here\u2019s the Challenge","volume":"9","author":"Kochhar","year":"2019","journal-title":"BMJ Open"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13318-018-0490-x","article-title":"Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients","volume":"44","author":"Saleh","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s40262-020-00904-z","article-title":"Population Pharmacokinetic Analysis and Exploratory Exposure\u2013Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A","volume":"59","author":"Retout","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40120-025-00723-z","article-title":"Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia","volume":"14","author":"Perlstein","year":"2025","journal-title":"Neurol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/psp4.70079","article-title":"Optimizing First-Line Therapeutics in Non-Small Cell Lung Cancer: Insights from Joint Modeling and Large-Scale Data Analysis","volume":"14","author":"Schneider","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40262-025-01506-3","article-title":"Population Pharmacokinetics and Pharmacodynamics of Fepixnebart (LY3016859) and Epiregulin in Patients with Chronic Pain","volume":"64","author":"James","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Marques, L., and Vale, N. (2024). Toward Personalized Salbutamol Therapy: Validating Virtual Patient-Derived Population Pharmacokinetic Model with Real-World Data. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16070881"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"D1358","DOI":"10.1093\/nar\/gkaa990","article-title":"PK-DB: Pharmacokinetics Database for Individualized and Stratified Computational Modeling","volume":"49","author":"Grzegorzewski","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"K\u00f6ller, A., Grzegorzewski, J., Tautenhahn, H.-M., and K\u00f6nig, M. (2021). Prediction of Survival After Partial Hepatectomy Using a Physiologically Based Pharmacokinetic Model of Indocyanine Green Liver Function Tests. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.730418"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Grzegorzewski, J., Brandhorst, J., and K\u00f6nig, M. (2022). Physiologically Based Pharmacokinetic (PBPK) Modeling of the Role of CYP2D6 Polymorphism for Metabolic Phenotyping with Dextromethorphan. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1029073"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Marques, L., Costa, B., and Vale, N. (2022). New Data for Nebivolol after In Silico PK Study: Focus on Young Patients and Dosage Regimen. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091911"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"FSO63","DOI":"10.4155\/fso.15.63","article-title":"Animal Models Are Essential to Biological Research: Issues and Perspectives","volume":"1","author":"Montagutelli","year":"2015","journal-title":"Future Sci. OA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41684-024-01458-4","article-title":"The Continued Importance of Animals in Biomedical Research","volume":"53","author":"Chang","year":"2024","journal-title":"Lab Anim."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s42826-022-00128-1","article-title":"Role of Animal Models in Biomedical Research: A Review","volume":"38","author":"Mukherjee","year":"2022","journal-title":"Lab. Anim. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000516240","article-title":"Animal Models in Pharmacology: A Brief History Awarding the Nobel Prizes for Physiology or Medicine","volume":"106","author":"Oliveira","year":"2021","journal-title":"Pharmacology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","article-title":"PBPK Modeling and Simulation in Drug Research and Development","volume":"6","author":"Zhuang","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species Differences between Mouse, Rat, Dog, Monkey and Human CYP-Mediated Drug Metabolism, Inhibition and Induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/17425255.2018.1499725","article-title":"Misconceptions and Issues Regarding Allometric Scaling during the Drug Development Process","volume":"14","author":"Mahmood","year":"2018","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/0976500X241299162","article-title":"A Comprehensive Analysis of Use of Small Laboratory Animals in Preclinical Research: A Five-Year Quantitative Descriptive Analysis","volume":"16","author":"Gattani","year":"2025","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Hartung, T. (2024). The (Misleading) Role of Animal Models in Drug Development. Front. Drug Discov., 4.","DOI":"10.3389\/fddsv.2024.1355044"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s41416-020-01033-x","article-title":"Pre-Clinical Animal Models Are Poor Predictors of Human Toxicities in Phase 1 Oncology Clinical Trials","volume":"123","author":"Atkins","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijsu.2019.10.015","article-title":"The Current State of Animal Models in Research: A Review","volume":"72","author":"Robinson","year":"2019","journal-title":"Int. J. Surg."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison of the Gastrointestinal Anatomy, Physiology, and Biochemistry of Humans and Commonly Used Laboratory Animals","volume":"16","author":"Kararli","year":"1995","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12967-019-1976-2","article-title":"Animal to Human Translation: A Systematic Scoping Review of Reported Concordance Rates","volume":"17","author":"Leenaars","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/bmj.39048.407928.BE","article-title":"Comparison of Treatment Effects between Animal Experiments and Clinical Trials: Systematic Review","volume":"334","author":"Perel","year":"2007","journal-title":"BMJ"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41392-022-01024-9","article-title":"Human Organoids in Basic Research and Clinical Applications","volume":"7","author":"Tang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2020.05.049","article-title":"Tissue Engineering of the Biliary Tract and Modelling of Cholestatic Disorders","volume":"73","author":"Brevini","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1247125","DOI":"10.1126\/science.1247125","article-title":"Organogenesis in a Dish: Modeling Development and Disease Using Organoid Technologies","volume":"345","author":"Lancaster","year":"2014","journal-title":"Science"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"100197","DOI":"10.1016\/j.crtox.2024.100197","article-title":"IPSC-Derived and Patient-Derived Organoids: Applications and Challenges in Scalability and Reproducibility as Pre-Clinical Models","volume":"7","author":"Heinzelmann","year":"2024","journal-title":"Curr. Res. Toxicol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"C151","DOI":"10.1152\/ajpcell.00120.2020","article-title":"A Brief History of Organoids","volume":"319","author":"Novellasdemunt","year":"2020","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1002\/mco2.274","article-title":"Organoids: The Current Status and Biomedical Applications","volume":"4","author":"Yang","year":"2023","journal-title":"MedComm"},{"key":"ref_106","first-page":"3015","article-title":"Deconstructing the Third Dimension\u2014How 3D Culture Microenvironments Alter Cellular Cues","volume":"125","author":"Baker","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41580-023-00583-1","article-title":"Cell\u2013Extracellular Matrix Mechanotransduction in 3D","volume":"24","author":"Saraswathibhatla","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 Stem Cells Build Crypt-Villus Structures in Vitro without a Mesenchymal Niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.reth.2019.11.004","article-title":"Organoid-Based Regenerative Medicine for Inflammatory Bowel Disease","volume":"13","author":"Okamoto","year":"2020","journal-title":"Regen. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Zhou, Z., Cong, L., and Cong, X. (2021). Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.762184"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"101046","DOI":"10.1016\/j.dmpk.2024.101046","article-title":"Advancements in Microphysiological Systems: Exploring Organoids and Organ-on-a-Chip Technologies in Drug Development -Focus on Pharmacokinetics Related Organs","volume":"60","author":"Kimura","year":"2025","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"100667","DOI":"10.1016\/j.medj.2025.100667","article-title":"Organoids and Organs-on-Chips: Recent Advances, Applications in Drug Development, and Regulatory Challenges","volume":"6","author":"Zhou","year":"2025","journal-title":"Med"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Li, B., Tang, Y., Huang, Z., Ma, L., Song, J., and Xue, L. (2025). Synergistic Innovation in Organ-on-a-Chip and Organoid Technologies: Reshaping the Future of Disease Modeling, Drug Development and Precision Medicine. Protein Cell, pwaf058.","DOI":"10.1093\/procel\/pwaf058"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"(2025). FDA Pushes to Replace Animal Testing. Nat. Biotechnol., 43, 655.","DOI":"10.1038\/s41587-025-02690-0"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"100089","DOI":"10.1016\/j.engmed.2025.100089","article-title":"Organoids Pharmacology and Toxicology","volume":"2","author":"Sun","year":"2025","journal-title":"EngMedicine"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0091270007312153","article-title":"New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process","volume":"48","author":"Huang","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/cts.13066","article-title":"3D Cell Culture Models: Drug Pharmacokinetics, Safety Assessment, and Regulatory Consideration","volume":"14","author":"Wang","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cpt.1458","article-title":"Liver Microphysiological Systems for Predicting and Evaluating Drug Effects","volume":"106","author":"Ribeiro","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1039\/C9LC00768G","article-title":"Liver Microphysiological Systems Development Guidelines for Safety Risk Assessment in the Pharmaceutical Industry","volume":"20","author":"Baudy","year":"2020","journal-title":"Lab Chip"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1039\/C9LC00857H","article-title":"Microphysiological Systems for ADME-Related Applications: Current Status and Recommendations for System Development and Characterization","volume":"20","author":"Fowler","year":"2020","journal-title":"Lab Chip"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41578-021-00279-y","article-title":"Engineering Organoids","volume":"6","author":"Hofer","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41576-019-0100-z","article-title":"Induced Pluripotent Stem Cells in Disease Modelling and Drug Discovery","volume":"20","author":"Rowe","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Kim, H.-Y., Charton, C., Shim, J.H., Lim, S.Y., Kim, J., Lee, S., Ohn, J.H., Kim, B.K., and Heo, C.Y. (2024). Patient-Derived Organoids Recapitulate Pathological Intrinsic and Phenotypic Features of Fibrous Dysplasia. Cells, 13.","DOI":"10.3390\/cells13090729"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","article-title":"Human Organoids: Model Systems for Human Biology and Medicine","volume":"21","author":"Kim","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1242\/dev.140731","article-title":"Pluripotent Stem Cell-Derived Organoids: Using Principles of Developmental Biology to Grow Human Tissues in a Dish","volume":"144","author":"McCauley","year":"2017","journal-title":"Development"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/mt.2011.41","article-title":"Comparison of Human Induced Pluripotent and Embryonic Stem Cells: Fraternal or Identical Twins?","volume":"19","author":"Narsinh","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/scrt365","article-title":"Toward a 3D Model of Human Brain Development for Studying Gene\/Environment Interactions","volume":"4","author":"Hogberg","year":"2013","journal-title":"Stem Cell Res. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature12517","article-title":"Cerebral Organoids Model Human Brain Development and Microcephaly","volume":"501","author":"Lancaster","year":"2013","journal-title":"Nature"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1582-4934.2007.00088.x","article-title":"Recent Advances in Cancer Stem\/Progenitor Cell Research: Therapeutic Implications for Overcoming Resistance to the Most Aggressive Cancers","volume":"11","author":"Mimeault","year":"2007","journal-title":"J. Cell Mol. Med."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Xu, Z., Yang, J., Xin, X., Liu, C., Li, L., Mei, X., and Li, M. (2023). Merits and Challenges of IPSC-Derived Organoids for Clinical Applications. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1188905"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Lee, H., Yang, S., Lee, K.J., Kim, S.-N., Jeong, J.-S., Kim, K.Y., Jung, C.-R., Jeon, S., Kwon, D., and Lee, S. (2024). Standardization and Quality Assessment for Human Intestinal Organoids. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1383893"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"14375","DOI":"10.1002\/cam4.5943","article-title":"Standardization of Organoid Culture in Cancer Research","volume":"12","author":"Zhou","year":"2023","journal-title":"Cancer Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"lnae016","DOI":"10.1093\/lifemedi\/lnae016","article-title":"Bridging the Organoid Translational Gap: Integrating Standardization and Micropatterning for Drug Screening in Clinical and Pharmaceutical Medicine","volume":"3","author":"Yang","year":"2024","journal-title":"Life Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1097\/CM9.0000000000003414","article-title":"Living Biobank: Standardization of Organoid Construction and Challenges","volume":"137","author":"Yang","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/adhm.201300151","article-title":"Rapid Prototyping of Concave Microwells for the Formation of 3D Multicellular Cancer Aggregates for Drug Screening","volume":"3","author":"Tu","year":"2014","journal-title":"Adv. Healthc. Mater."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"044109","DOI":"10.1063\/1.4766300","article-title":"Polyester \u03bc-Assay Chip for Stem Cell Studies","volume":"6","author":"Piraino","year":"2012","journal-title":"Biomicrofluidics"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1039\/c1lc20213h","article-title":"Microfabricated Polyester Conical Microwells for Cell Culture Applications","volume":"11","author":"Piraino","year":"2011","journal-title":"Lab Chip"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41551-020-0565-2","article-title":"High-Throughput Automated Organoid Culture via Stem-Cell Aggregation in Microcavity Arrays","volume":"4","author":"Brandenberg","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"101335","DOI":"10.1016\/j.xcrm.2023.101335","article-title":"Unified Framework for Patient-Derived, Tumor-Organoid-Based Predictive Testing of Standard-of-Care Therapies in Metastatic Colorectal Cancer","volume":"4","author":"Tan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nature20168","article-title":"Designer Matrices for Intestinal Stem Cell and Organoid Culture","volume":"539","author":"Gjorevski","year":"2016","journal-title":"Nature"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1902042","DOI":"10.1002\/adma.201902042","article-title":"Advances in Hydrogels in Organoids and Organs-on-a-Chip","volume":"31","author":"Liu","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/acsomega.1c05136","article-title":"Synthetic Matrices for Intestinal Organoid Culture: Implications for Better Performance","volume":"7","author":"Poudel","year":"2022","journal-title":"ACS Omega"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e43028","DOI":"10.1016\/j.heliyon.2025.e43028","article-title":"Organoid: Biomedical Application, Biobanking, and Pathways to Translation","volume":"11","author":"Sinha","year":"2025","journal-title":"Heliyon"},{"key":"ref_144","first-page":"17","article-title":"Organoid Biobanks as a New Tool for Pre-Clinical Validation of Candidate Drug Efficacy and Safety","volume":"13","author":"Botti","year":"2021","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"ref_145","unstructured":"(2025, August 19). Foundation Hubrecht Organoid Biobank. Available online: https:\/\/www.hubrechtorganoidbiobank.org."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/s41598-023-29065-2","article-title":"Tumor Organoid Biobank-New Platform for Medical Research","volume":"13","author":"Xie","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Licata, J.P., Schwab, K.H., Har-el, Y., Gerstenhaber, J.A., and Lelkes, P.I. (2023). Bioreactor Technologies for Enhanced Organoid Culture. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411427"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"100903","DOI":"10.1016\/j.crmeth.2024.100903","article-title":"Accelerated Production of Human Epithelial Organoids in a Miniaturized Spinning Bioreactor","volume":"4","author":"Ye","year":"2024","journal-title":"Cell Rep. Methods"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nprot.2017.152","article-title":"Generation of Human Brain Region\u2013Specific Organoids Using a Miniaturized Spinning Bioreactor","volume":"13","author":"Qian","year":"2018","journal-title":"Nat. Protoc."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1039\/C7IB00024C","article-title":"Integrating Perfusable Vascular Networks with a Three-Dimensional Tissue in a Microfluidic Device","volume":"9","author":"Nashimoto","year":"2017","journal-title":"Integr. Biol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.stemcr.2018.01.041","article-title":"Renal Subcapsular Transplantation of PSC-Derived Kidney Organoids Induces Neo-Vasculogenesis and Significant Glomerular and Tubular Maturation In Vivo","volume":"10","author":"Ritsma","year":"2018","journal-title":"Stem Cell Rep."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Zhao, X., Xu, Z., Xiao, L., Shi, T., Xiao, H., Wang, Y., Li, Y., Xue, F., and Zeng, W. (2021). Review on the Vascularization of Organoids and Organoids-on-a-Chip. Front. Bioeng. Biotechnol., 9.","DOI":"10.3389\/fbioe.2021.637048"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e76707","DOI":"10.7554\/eLife.76707","article-title":"Generation of Vascularized Brain Organoids to Study Neurovascular Interactions","volume":"11","author":"Sun","year":"2022","journal-title":"eLife"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43586-022-00118-6","article-title":"A Guide to the Organ-on-a-Chip","volume":"2","author":"Leung","year":"2022","journal-title":"Nat. Rev. Methods Primers"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"100246","DOI":"10.1016\/j.apsadv.2022.100246","article-title":"Journey of Organ on a Chip Technology and Its Role in Future Healthcare Scenario","volume":"9","author":"Singh","year":"2022","journal-title":"Appl. Surf. Sci. Adv."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.1038\/s41598-025-91826-y","article-title":"In Vivo Transplantation of Mammalian Vascular Organoids onto the Chick Chorioallantoic Membrane Reveals the Formation of a Hierarchical Vascular Network","volume":"15","author":"Kowalski","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"118529","DOI":"10.1016\/j.atherosclerosis.2024.118529","article-title":"Engineering next Generation Vascularized Organoids","volume":"398","author":"Werschler","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Konoe, R., and Morizane, R. (2023). Strategies for Improving Vascularization in Kidney Organoids: A Review of Current Trends. Biology, 12.","DOI":"10.3390\/biology12040503"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41586-020-1962-0","article-title":"Cell Stress in Cortical Organoids Impairs Molecular Subtype Specification","volume":"578","author":"Bhaduri","year":"2020","journal-title":"Nature"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"dev166074","DOI":"10.1242\/dev.166074","article-title":"Brain Organoids: Advances, Applications and Challenges","volume":"146","author":"Qian","year":"2019","journal-title":"Development"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"LaMontagne, E., Muotri, A.R., and Engler, A.J. (2022). Recent Advancements and Future Requirements in Vascularization of Cortical Organoids. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.1048731"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1021\/acssensors.4c00004","article-title":"From Organ-on-a-Chip to Human-on-a-Chip: A Review of Research Progress and Latest Applications","volume":"9","author":"Huang","year":"2024","journal-title":"ACS Sens."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.semcdb.2022.10.001","article-title":"Microfluidic Organoids-on-a-Chip: The Future of Human Models","volume":"144","author":"Saorin","year":"2023","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature09691","article-title":"Directed Differentiation of Human Pluripotent Stem Cells into Intestinal Tissue in Vitro","volume":"470","author":"Spence","year":"2011","journal-title":"Nature"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e33736","DOI":"10.1016\/j.heliyon.2024.e33736","article-title":"Reprogramming Human Urine Cells into Intestinal Organoids with Long-Term Expansion Ability and Barrier Function","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"ref_166","first-page":"116","article-title":"Rational Design of Oral Drugs Targeting Mucosa Delivery with Gut Organoid Platforms","volume":"30","author":"Tong","year":"2023","journal-title":"Bioact. Mater."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.stemcr.2017.11.004","article-title":"A Refined Culture System for Human Induced Pluripotent Stem Cell-Derived Intestinal Epithelial Organoids","volume":"10","author":"Takahashi","year":"2018","journal-title":"Stem Cell Rep."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"104928","DOI":"10.1016\/j.tiv.2020.104928","article-title":"Human Ileal Organoid Model Recapitulates Clinical Incidence of Diarrhea Associated with Small Molecule Drugs","volume":"68","author":"Belair","year":"2020","journal-title":"Toxicol. Vitr."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/toxsci\/kfy268","article-title":"Human 3D Gastrointestinal Microtissue Barrier Function As a Predictor of Drug-Induced Diarrhea","volume":"168","author":"Peters","year":"2019","journal-title":"Toxicol. Sci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"102374","DOI":"10.1016\/j.xpro.2023.102374","article-title":"Protocol to Generate Large Human Intestinal Organoids Using a Rotating Bioreactor","volume":"4","author":"Takahashi","year":"2023","journal-title":"STAR Protoc."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1002\/cpim.106","article-title":"Establishment and Culture of Human Intestinal Organoids Derived from Adult Stem Cells","volume":"130","author":"Puschhof","year":"2020","journal-title":"Curr. Protoc. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1124\/dmd.118.080374","article-title":"Generation of Intestinal Organoids Suitable for Pharmacokinetic Studies from Human Induced Pluripotent Stem Cells","volume":"46","author":"Onozato","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bbrc.2012.01.155","article-title":"Real-Time Analysis of P-Glycoprotein-Mediated Drug Transport across Primary Intestinal Epithelium Three-Dimensionally Cultured in Vitro","volume":"419","author":"Mizutani","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/bcpt.12596","article-title":"Measurement of Rhodamine 123 in Three-Dimensional Organoids: A Novel Model for P-Glycoprotein Inhibitor Screening","volume":"119","author":"Zhang","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"11403","DOI":"10.1038\/s41598-025-95823-z","article-title":"Robust and Reproducible Human Intestinal Organoid-Derived Monolayer Model for Analyzing Drug Absorption","volume":"15","author":"Tanaka","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"151489","DOI":"10.1016\/j.ejcb.2025.151489","article-title":"Human Pluripotent Stem Cell-Derived Intestinal Organoids for Pharmacokinetic Studies","volume":"104","author":"Saito","year":"2025","journal-title":"Eur. J. Cell Biol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.stem.2018.11.016","article-title":"Human Intestinal Organoids Maintain Self-Renewal Capacity and Cellular Diversity in Niche-Inspired Culture Condition","volume":"23","author":"Fujii","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","article-title":"Long-Term Expansion of Epithelial Organoids from Human Colon, Adenoma, Adenocarcinoma, and Barrett\u2019s Epithelium","volume":"141","author":"Sato","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Matsui, T., and Shinozawa, T. (2021). Human Organoids for Predictive Toxicology Research and Drug Development. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.767621"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmgh.2017.12.010","article-title":"Microfluidic Organ-on-a-Chip Models of Human Intestine","volume":"5","author":"Bein","year":"2018","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1038\/s41598-018-21201-7","article-title":"Development of a Primary Human Small Intestine-on-a-Chip Using Biopsy-Derived Organoids","volume":"8","author":"Kasendra","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ydbio.2016.10.017","article-title":"Organoids: A New in Vitro Model System for Biomedical Science and Disease Modelling and Promising Source for Cell-Based Transplantation","volume":"420","author":"Koo","year":"2016","journal-title":"Dev. Biol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41576-018-0051-9","article-title":"Progress and Potential in Organoid Research","volume":"19","author":"Rossi","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s43188-025-00289-w","article-title":"Advancing Hepatotoxicity Assessment: Current Advances and Future Directions","volume":"41","author":"Kim","year":"2025","journal-title":"Toxicol. Res."},{"key":"ref_186","first-page":"677","article-title":"Proceedings of a Workshop to Address Animal Methods Bias in Scientific Publishing","volume":"40","author":"Krebs","year":"2022","journal-title":"ALTEX"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13578-023-01136-x","article-title":"Liver Organoid Culture Methods","volume":"13","author":"Hu","year":"2023","journal-title":"Cell Biosci."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13287-024-03865-3","article-title":"Liver Organoids: Updates on Generation Strategies and Biomedical Applications","volume":"15","author":"Liu","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jhep.2019.06.030","article-title":"Generation of Expandable Human Pluripotent Stem Cell-Derived Hepatocyte-Like Liver Organoids","volume":"71","author":"Mun","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"121575","DOI":"10.1016\/j.biomaterials.2022.121575","article-title":"Development of Human Pluripotent Stem Cell-Derived Hepatic Organoids as an Alternative Model for Drug Safety Assessment","volume":"286","author":"Kim","year":"2022","journal-title":"Biomaterials"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1089\/scd.2017.0023","article-title":"A Scalable Approach for the Generation of Human Pluripotent Stem Cell-Derived Hepatic Organoids with Sensitive Hepatotoxicity Features","volume":"26","author":"Sgodda","year":"2017","journal-title":"Stem Cells Dev."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Forsythe, S.D., Devarasetty, M., Shupe, T., Bishop, C., Atala, A., Soker, S., and Skardal, A. (2018). Environmental Toxin Screening Using Human-Derived 3D Bioengineered Liver and Cardiac Organoids. Front. Public Health, 6.","DOI":"10.3389\/fpubh.2018.00103"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1053\/j.gastro.2020.10.002","article-title":"High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell\u2013Derived Organoids","volume":"160","author":"Shinozawa","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1053\/j.gastro.2018.01.066","article-title":"Biotechnology Challenges to In Vitro Maturation of Hepatic Stem Cells","volume":"154","author":"Chen","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Scheidecker, B., Shinohara, M., Sugimoto, M., Danoy, M., Nishikawa, M., and Sakai, Y. (2020). Induction of in Vitro Metabolic Zonation in Primary Hepatocytes Requires Both Near-Physiological Oxygen Concentration and Flux. Front. Bioeng. Biotechnol., 8.","DOI":"10.3389\/fbioe.2020.00524"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/bit.28640","article-title":"A Highly Efficient Cell Culture Method Using Oxygen-permeable PDMS-based Honeycomb Microwells Produces Functional Liver Organoids from Human Induced Pluripotent Stem Cell-derived Carboxypeptidase M Liver Progenitor Cells","volume":"121","author":"Utami","year":"2024","journal-title":"Biotechnol. Bioeng."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00441-021-03565-x","article-title":"Kidney Organoids: Current Knowledge and Future Directions","volume":"387","author":"Ahmadi","year":"2022","journal-title":"Cell Tissue Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1101\/gad.329573.119","article-title":"Kidney Organoids: Accurate Models or Fortunate Accidents","volume":"33","author":"Little","year":"2019","journal-title":"Genes. Dev."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Chen, W.-Y., Evangelista, E.A., Yang, J., Kelly, E.J., and Yeung, C.K. (2021). Kidney Organoid and Microphysiological Kidney Chip Models to Accelerate Drug Development and Reduce Animal Testing. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.695920"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","article-title":"Trends in Clinical Success Rates and Therapeutic Focus","volume":"18","author":"Dowden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nrd.2016.184","article-title":"Phase II and Phase III Failures: 2013\u20132015","volume":"15","author":"Harrison","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of Clinical Drug Development Fails and How to Improve It?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41581-018-0003-9","article-title":"Advances in Predictive in Vitro Models of Drug-Induced Nephrotoxicity","volume":"14","author":"Soo","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2215\/CJN.00860115","article-title":"Drug-Induced Glomerular Disease","volume":"10","author":"Markowitz","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.stem.2018.04.022","article-title":"High-Throughput Screening Enhances Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping","volume":"22","author":"Czerniecki","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"DesRochers, T.M., Suter, L., Roth, A., and Kaplan, D.L. (2013). Bioengineered 3D Human Kidney Tissue, a Platform for the Determination of Nephrotoxicity. PLoS ONE, 8.","DOI":"10.1371\/annotation\/fb32f1b8-7397-40be-bbf9-b80e67763043"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature15695","article-title":"Kidney Organoids from Human IPS Cells Contain Multiple Lineages and Model Human Nephrogenesis","volume":"526","author":"Takasato","year":"2015","journal-title":"Nature"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1042\/BST20231554","article-title":"Kidney Organoids: Steps towards Better Organization and Function","volume":"52","author":"Davies","year":"2024","journal-title":"Biochem. Soc. Trans."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cpt.1537","article-title":"Toward a Consensus on Applying Quantitative Liquid Chromatography-Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper","volume":"106","author":"Prasad","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1124\/dmd.116.072066","article-title":"Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics","volume":"44","author":"Prasad","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.ki.5000170","article-title":"Organic Anion and Cation Transporter Expression and Function during Embryonic Kidney Development and in Organ Culture Models","volume":"69","author":"Sweet","year":"2006","journal-title":"Kidney Int."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.V134866","article-title":"Gene Expression Levels and Immunolocalization of Organic Ion Transporters in the Human Kidney","volume":"13","author":"Motohashi","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/psp4.12553","article-title":"Novel Mechanistic PBPK Model to Predict Renal Clearance in Varying Stages of CKD by Incorporating Tubular Adaptation and Dynamic Passive Reabsorption","volume":"9","author":"Huang","year":"2020","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"B\u00fcning, A., and Reckzeh, E. (2025). Opportunities of Patient-derived Organoids in Drug Development. Br. J. Pharmacol., 1\u20136.","DOI":"10.1111\/bph.70010"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"216180","DOI":"10.1016\/j.canlet.2023.216180","article-title":"Patient-Derived Organoids in Translational Oncology and Drug Screening","volume":"562","author":"Yang","year":"2023","journal-title":"Cancer Lett."}],"container-title":["Future Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-9879\/5\/4\/74\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:36:52Z","timestamp":1766036212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-9879\/5\/4\/74"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":215,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["futurepharmacol5040074"],"URL":"https:\/\/doi.org\/10.3390\/futurepharmacol5040074","relation":{},"ISSN":["2673-9879"],"issn-type":[{"value":"2673-9879","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}